PTC Therapeutics, Inc. Increase (Decrease) in Contract with Customer, Liability
PTC Therapeutics, Inc. (PTCT) reported Increase (Decrease) in Contract with Customer, Liability of -$804.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-07-30
- PTC Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $718.00K.
- PTC Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$1.52M, a 121.14% decline year-over-year.
- PTC Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $300.00K, a 94.75% decline year-over-year.
- PTC Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$8.14M.
- PTC Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$4.00M, a 181.31% decline from fiscal 2024.
- PTC Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $4.92M.
- PTC Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$550.00K, a 140.71% decline from fiscal 2022.
- PTC Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was $1.35M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $718.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$804.00K 10-Q · filed 2026-07-30 | -$504.00K derived: sum of 3 quarters · filed 2026-07-30 | -$8.65M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$1.52M 10-Q · filed 2026-05-07 | -$1.22M derived: sum of 2 quarters · filed 2026-05-07 | -$9.37M derived: sum of 3 quarters · filed 2026-05-07 | -$12.72M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$7.84M derived: sum of 2 quarters · filed 2026-02-19 | -$11.20M derived: sum of 3 quarters · filed 2026-07-30 | -$4.00M 10-K · filed 2026-02-19 |
| 2025-09-30 | -$8.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$11.50M derived: sum of 2 quarters · filed 2026-07-30 | -$4.30M 10-Q · filed 2025-11-04 | $1.42M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$3.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $3.85M 10-Q · filed 2026-07-30 | $9.56M derived: sum of 3 quarters · filed 2026-07-30 | $9.56M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $7.20M 10-Q · filed 2026-05-07 | $12.92M derived: sum of 2 quarters · filed 2026-05-07 | $12.92M derived: sum of 3 quarters · filed 2026-05-07 | $12.92M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $5.72M derived: sum of 2 quarters · filed 2026-02-19 | $5.72M derived: sum of 3 quarters · filed 2026-02-19 | $4.92M 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | -$801.00K 10-Q · filed 2025-11-04 | -$1.22M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$801.00K 10-Q · filed 2025-08-07 | -$1.22M derived: sum of 3 quarters · filed 2026-02-19 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$801.00K 10-Q · filed 2025-05-06 | -$1.22M derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | -$214.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$423.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $801.00K derived: sum of 2 quarters · filed 2026-02-19 | $587.00K derived: sum of 3 quarters · filed 2026-02-19 | -$550.00K 10-K · filed 2026-02-19 |
| 2023-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.01M derived: sum of 2 quarters · filed 2024-11-07 | -$127.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$214.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.35M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$1.14M 10-Q · filed 2024-04-25 | |||
| 2022-12-31 | $1.35M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $75.00K derived: sum of 2 quarters · filed 2024-02-29 | -$1.86M derived: sum of 3 quarters · filed 2024-02-29 | -$4.01M 10-K · filed 2024-02-29 |
| 2021-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | -$1.90M derived: sum of 2 quarters · filed 2022-10-27 | -$4.05M 10-Q · filed 2022-10-27 | -$6.15M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | -$1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$4.08M 10-Q · filed 2022-08-04 | -$6.18M derived: sum of 3 quarters · filed 2023-02-21 | -$8.19M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | -$2.15M 10-Q · filed 2022-05-03 | -$4.25M derived: sum of 2 quarters · filed 2023-02-21 | -$6.26M derived: sum of 3 quarters · filed 2023-02-21 | -$8.99M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | -$2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$4.11M derived: sum of 2 quarters · filed 2023-02-21 | -$6.83M derived: sum of 3 quarters · filed 2023-02-21 | -$8.03M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | -$4.74M derived: sum of 2 quarters · filed 2021-10-28 | -$5.94M 10-Q · filed 2021-10-28 | -$8.91M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | -$2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$3.92M 10-Q · filed 2021-07-29 | -$6.89M derived: sum of 3 quarters · filed 2022-02-22 | -$7.82M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | -$1.20M 10-Q · filed 2021-05-04 | -$4.17M derived: sum of 2 quarters · filed 2022-02-22 | -$5.10M derived: sum of 3 quarters · filed 2022-02-22 | -$3.16M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | -$2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | -$3.90M derived: sum of 2 quarters · filed 2022-02-22 | -$1.96M derived: sum of 3 quarters · filed 2022-02-22 | -$1.39M 10-K · filed 2022-02-22 |
| 2019-09-30 | -$930.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $1.01M derived: sum of 2 quarters · filed 2020-10-29 | $1.58M 10-Q · filed 2020-10-29 | $2.16M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $2.51M 10-Q · filed 2020-08-05 | $3.09M derived: sum of 3 quarters · filed 2021-02-25 | $5.82M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $574.00K 10-Q · filed 2020-04-30 | $1.16M derived: sum of 2 quarters · filed 2021-02-25 | $3.88M derived: sum of 3 quarters · filed 2021-02-25 | $5.68M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $581.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.31M derived: sum of 2 quarters · filed 2021-02-25 | $5.11M derived: sum of 3 quarters · filed 2021-02-25 | $6.51M 10-K · filed 2021-02-25 |
| 2018-09-30 | $2.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $4.52M derived: sum of 2 quarters · filed 2019-10-30 | $5.93M 10-Q · filed 2019-10-30 | $4.69M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $3.20M 10-Q · filed 2019-08-06 | $1.96M derived: sum of 3 quarters · filed 2020-03-02 | $8.07M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $1.41M 10-Q · filed 2019-05-02 | $168.00K derived: sum of 2 quarters · filed 2020-03-02 | $6.27M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $4.87M derived: sum of 2 quarters · filed 2020-03-02 | $9.47M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $6.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $10.71M 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | $4.60M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $1.53M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |